To review the efficacy, safety, and durability of teprotumumab (TEP) in the treatment of dysthyroid optic neuropathy (DON).
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change for audiologists — this systematic review concerns an ophthalmologic condition with minimal direct hearing-health relevance.
Teprotumumab has a known side-effect profile that includes hearing-related adverse events (such as sensorineural hearing loss and tinnitus), so audiologists may encounter patients on this drug who need hearing monitoring.
- 01Systematic review and pooled analysis of 81 eyes treated with teprotumumab for dysthyroid optic neuropathy.
- 02Primary focus is ophthalmologic efficacy, safety, and treatment durability — not audiology.
- 03Teprotumumab is known from prior literature to carry a risk of hearing-related adverse events (ototoxicity).
- 04No primary hearing outcome data are reported in this study.
- 05Audiologists should be aware that patients on teprotumumab may warrant hearing monitoring.
Teprotumumab is effective for treating dysthyroid optic neuropathy based on pooled analysis of 81 eyes.
studypartially supportedTeprotumumab demonstrates acceptable safety and durable outcomes for dysthyroid optic neuropathy.
studypartially supported- PMID
- 43046497
- DOI
- 10.1080/01676830.2026.2760368.
- Journal
- Journal of Neuro-Ophthalmology
- Publication type
- meta_analysis
- Evidence level
- 1a
- Sample size
- 81
- Population
- Patients with dysthyroid optic neuropathy treated with teprotumumab (81 eyes)
- Intervention
- Teprotumumab (IGF-1R inhibitor) for dysthyroid optic neuropathy
Primary outcomes
Visual outcomes (efficacy); Safety profile; Durability of treatment response